Global Patent Index - EP 2089014 A4

EP 2089014 A4 20091209 - OMEGA-3 FATTY ACIDS AND DYSLIPIDEMIC AGENT FOR REDUCTION OF APO-B LEVELS

Title (en)

OMEGA-3 FATTY ACIDS AND DYSLIPIDEMIC AGENT FOR REDUCTION OF APO-B LEVELS

Title (de)

OMEGA-3-FETTSÄUREN UND MITTEL GEGEN DYSLIPIDÄMIE ZUR SENKUNG DES APO-B-SPIEGELS

Title (fr)

ACIDES GRAS OMÉGA-3 ET AGENT DYSLIPIDÉMIQUE POUR LA RÉDUCTION DES NIVEAUX D'APO-B

Publication

EP 2089014 A4 20091209 (EN)

Application

EP 07852630 A 20071010

Priority

  • US 2007021631 W 20071010
  • US 85028006 P 20061010

Abstract (en)

[origin: WO2008045465A1] Methods of utilizing a combined administration or a unit dosage of a combination of a dyslipidemic agent and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypercholesterolemia, hypertriglyceridemia, mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.

IPC 8 full level

A61K 31/20 (2006.01); A61K 31/232 (2006.01); A61K 31/351 (2006.01); A61K 31/366 (2006.01); A61P 3/06 (2006.01); A61P 9/00 (2006.01)

CPC (source: EP KR)

A61K 31/20 (2013.01 - EP KR); A61K 31/232 (2013.01 - EP); A61K 31/366 (2013.01 - EP); A61K 45/06 (2013.01 - EP); A61P 3/06 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 43/00 (2017.12 - EP)

Citation (search report)

  • [XPI] WO 2007011886 A2 20070125 - RELIANT PHARMACEUTICALS INC [US], et al
  • [XI] US 2003170643 A1 20030911 - FISHER EDWARD [US], et al
  • [XI] DURRINGTON P N ET AL: "An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased trigycerides in simvastatin treated patients with coronary heart disease and persisting hyperlipidemia", HEART, BMJ, LONDON, GB, vol. 85, 1 January 2001 (2001-01-01), pages 544 - 548, XP003011854, ISSN: 1355-6037
  • [XI] NORDOY ET AL: "n-3 fatty acids as supplement to statins in the treatment of patients with combined hyperlipidemia'", ESSENTIAL FATTY ACIDS AND EICOSANOIDS: INVITED PAPERS FROM THEINTERNATIONAL CONGRESS, XX, XX, 1 January 1998 (1998-01-01), pages 256 - 261, XP008081086
  • [XI] CHAN ET AL: "Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia", DIABETES,, vol. 51, 1 January 2002 (2002-01-01), pages 2377 - 2386, XP008108930
  • See references of WO 2008045465A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

Designated extension state (EPC)

HR

DOCDB simple family (publication)

WO 2008045465 A1 20080417; AU 2007307007 A1 20080417; BR PI0719182 A2 20141021; CA 2672919 A1 20080417; CN 101553220 A 20091007; CN 101553221 A 20091007; EA 018734 B1 20131030; EA 200970359 A1 20091030; EA 200970360 A1 20091030; EP 2089014 A1 20090819; EP 2089014 A4 20091209; JP 2010505956 A 20100225; KR 20090080070 A 20090723; MX 2009003921 A 20090831

DOCDB simple family (application)

US 2007021631 W 20071010; AU 2007307007 A 20071010; BR PI0719182 A 20071010; CA 2672919 A 20071010; CN 200780045648 A 20070907; CN 200780045666 A 20071010; EA 200970359 A 20070907; EA 200970360 A 20071010; EP 07852630 A 20071010; JP 2009532391 A 20071010; KR 20097009523 A 20071010; MX 2009003921 A 20071010